Abstract:OBJECTIVES To evaluate the in vivo antibacterial efficacy of chinfloxacin, a novel fluoroquinolone, in murine systemic and local infection models. METHODS The efficacy of chinfloxacin in systemic infection was evaluated in a mouse peritonitis model using isolates of methicillin-susceptible Staphylococcus aureus (MSSA, n = 3), methicillin-resistant Staphylococcus aureus (MRSA; n = 1), penicillin-intermediate Streptococcus pneumoniae (PISP; n = 1), penicillin-resistant S. pneumoniae (PRSP; n = 2), vancomycin-susceptible Enterococcus faecalis (VSE; n = 1), vancomycin-resistant E. faecalis (VRE; n = 2), Escherichia coli (n = 3) and Klebsiella pneumoniae (n = 2). The local infections included mouse pulmonary infections caused by penicillin-susceptible S. pneumoniae (PSSP; n = 1), PRSP (n = 1) and K. pneumoniae (n = 2). RESULTS In the mouse systemic infection model, chinfloxacin demonstrated potent activity against MSSA [50% effective dose (ED(50)) 2.28-4.15 mg/kg], MRSA (ED(50) 14.75 mg/kg), PISP (ED(50) 6.20 mg/kg), PRSP (ED(50) 3.51-5.03 mg/kg), VSE (ED(50) 25.02 mg/kg), VRE (ED(50) 5.18-15.39 mg/kg), E. coli (ED(50) 1.25-1.90 mg/kg) and K. pneumoniae (ED(50) 2.92-8.28 mg/kg). The therapeutic efficacy of chinfloxacin was generally similar to (P > 0.05) that of moxifloxacin, significantly higher (P < 0.01 or P < 0.05) than that of levofloxacin in Gram-positive isolate infections (MSSA, MRSA, PISP, PRSP, VSE and VRE), and less than that of levofloxacin against E. coli and K. pneumoniae infections (P < 0.01). In the mouse pulmonary infection model, chinfloxacin showed potent activity towards S. pneumoniae (higher than levofloxacin and ciprofloxacin) and K. pneumoniae (lower than levofloxacin and similar to or higher than ciprofloxacin) infections. CONCLUSIONS The results validated the potent efficacy of chinfloxacin in vivo. The high efficacy of chinfloxacin in murine systemic and local infections warrants investigation of its clinical use.

Pharmacokinetics/pharmacodynamics of Antofloxacin Hydrochloride in a Neutropenic Murine Thigh Model Ofstaphylococcus Aureusinfection

In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin Against Klebsiella Pneumoniae in a Neutropenic Murine Lung Infection Model.

In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin Against Escherichia Coli in a Neutropenic Murine Thigh Infection Model.

In Vivo Pharmacodynamic Target Assessment of Antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Neutropenic Murine Pneumonia Model

Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.

Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Staphylococcus Aureus Infection

Pharmacokinetics of Antofloxacin Hydrochloride, a Novel Fluoroquinolone, after Single-Dose Intravenous Administration in Healthy Chinese Male Volunteers.

Pharmacokinetics of Antofloxacin Hydrochloride in Healthy Male Subjects after Multiple Intravenous Dose Administration.

Dose Findings of Antofloxacin Hydrochloride for Treating Bacterial Infections in an Early Clinical Trial Using PK-PD Parameters in Healthy Volunteers

Pharmacokinetic Study of Single and Multiple Oral Dose Administration of Antofloxacin Hydrochloride in Healthy Male Volunteers.

A Phase Ii Study of Antofloxacin Hydrochloride, A Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections

The In-Vitro Sustained Effects of Antofloxacin Hydrochloride against Staphylococcus Aureus and Escherichia Coli

Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization

Sitafloxacin Pharmacokinetics/pharmacodynamics Against Multidrug-Resistant Bacteria in a Dynamic Urinary Tract Infection in Vitro Model.

Pharmacokinetics and Pharmacodynamics of a Novel Vancomycin Derivative LYSC98 in a Murine Thigh Infection Model Against Staphylococcus Aureus

Pharmacokinetic and pharmacodynamic analysis of flomoxef against the clinical isolates of strains

Pharmacodynamic effect of norfloxacin against Aeromonas hydrophila in vitro pharmacokinetic model

In Vivo Antibacterial Activity of Chinfloxacin, A New Fluoroquinolone Antibiotic

Tolerability and Pharmacokinetics of Antofloxacin Hydrochloride after Multiple Oral Dose Administration in Healthy Chinese Male Volunteers.

The Influence of a Newly Developed Quinolone: Antoflox-acin, on CYP Activity in Rats

In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.